Art. -Nr.: HY-121225

Faradiol

Name: Faradiol
Brand: MedChemExpress
SKU: HY-121225
Price: 540.00 USD
Availability: InStock
Rating: 5 (1 reviews)

Faradiol is a STAT3 inhibitor. Faradiol exerts anti-inflammatory activity by reducing STAT3 phosphorylation in a concentration-dependent manner and inhibiting LPS-induced IL-6 release from human monocytes, while also exhibiting cytotoxicity against leukemia and non-small cell lung cancer cells. Faradiol can be used in research on leukemia, edema, cancer, non-small cell lung cancer, Phorbol 12-myristate 13-acetate (TPA) (HY-18739)-induced inflammation, and skin tumors.

Nur für Forschungszwecke. Wir verkaufen nicht an Patienten.

CAS. Nr.: 20554-95-4
Formel: C₃₀H₅₀O₂
Molecular Weight:442.72

Speicherung:

Please store the product under the recommended conditions in the Certificate of Analysis.

Data Sheet (284 KB)

Faradiol Chemical Structure

CAS. Nr.: 20554-95-4

Größe

Preis

Verfügbarkeit

Menge

Amount: USD 0.00

* Bitte wählen Sie Menge, bevor Sie Artikel hinzufügen.

Top Publications Citing

Use of MCE Products

Fluorescent Dye

Strong Fluorescence Signal / Multi-Disciplinary Applications / High Fluorescence Specificity

Biologische Aktivität
- Beschreibung
- IC₅₀ & Target
- Cellular Effect
- In Vitro
- In Vivo
Chemical Information
Reinheit & Dokumentation
Verweise
Calculators
Help & FAQs
Classifications
Bioz

Biologische Aktivität

Beschreibung

IC₅₀ & Target

^[2]

STAT3

IL-6

Alle STAT Isoform-spezifische Produkte anzeigen :

Alle Interleukin Related Isoform-spezifische Produkte anzeigen :

Cellular Effect

Cell Line	Type	Value	Description	References
NB-4	IC50	32.47 μM	Cytotoxicity against human NB4 cells assessed as 50% loss of metabolic activity after 24 hrs by MTT assay. Cytotoxicity against human NB4 cells assessed as 50% loss of metabolic activity after 24 hrs by MTT assay.	20981868
NB-4	IC50	30.60 μM	Cytotoxicity against human NB4 cells assessed as 50% loss of metabolic activity after 48 hrs by MTT assay. Cytotoxicity against human NB4 cells assessed as 50% loss of metabolic activity after 48 hrs by MTT assay.	20981868
K562	IC50	132.80 μM	Cytotoxicity against human K562 cells assessed as 50% loss of metabolic activity after 24 hrs by MTT assay. Cytotoxicity against human K562 cells assessed as 50% loss of metabolic activity after 24 hrs by MTT assay.	20981868
K562	IC50	60.15 μM	Cytotoxicity against human K562 cells assessed as 50% loss of metabolic activity after 48 hrs by MTT assay. Cytotoxicity against human K562 cells assessed as 50% loss of metabolic activity after 48 hrs by MTT assay.	20981868
CCRF-CEM	GI50	3.2 μM	Antiproliferative activity against human CCRF-CEM leukemia cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay. Antiproliferative activity against human CCRF-CEM leukemia cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay.	11809525
SR	GI50	3.5 μM	Antiproliferative activity against human SR leukemia cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay. Antiproliferative activity against human SR leukemia cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay.	11809525
EKVX	GI50	2.2 μM	Antiproliferative activity against human EKVX non-small cell lung cancer cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay. Antiproliferative activity against human EKVX non-small cell lung cancer cells assessed as growth inhibition after 48 hrs continuous exposure by sulforhodamine B protein assay.	11809525

In Vitro

Anti-cancerInnate ImmunityCytokines & ChemokinesViral InfectionOthers

Anti-cancer

Faradiol (starting concentration 100 μM; 24-48 h) exhibits low MTT cytotoxicity in human leukemia NB4 and K562 cells, with IC₅₀ values of 32.47 μM (NB4, 24 h) and 132.80 μM (K562, 24 h), respectively^[4].
Faradiol (10^-4 M; 48 h) exhibits selective cytotoxicity against CCRF-CEM, K-582, SR, and EKVX human cancer cell lines, with GI₅₀ values of 2.2-4.2 µM, and shows moderate cytotoxicity against the remaining tested NCI 60 cell lines (GI₅₀, 10.5-86.9 µM)^[6].

Innate Immunity

Cytokines & Chemokines

Faradiol (5-20 μM; preincubation for 30 min; LPS stimulation for 3-24 h) reduces LPS-induced IL-6 release from THP-1 monocytes, with concentration-dependent activity over the range of 5 to 20 μM, inhibiting IL-6 release by 59% at 20 μM^[1].
Faradiol (20 μM) reduces STAT3 phosphorylation in THP-1 monocytes without affecting NF-κB p65 phosphorylation^[1].
Faradiol (20 µM; 30 min-24 h) inhibits LPS-induced IL-6 release in THP-1 human monocytes by 59%^[2].
Faradiol (20 µM) reduces STAT3 phosphorylation but not NF-κB p65 phosphorylation in THP-1 human monocytes^[2].

Viral Infection

Faradiol (compound 1) (32 nmol; 48 h) inhibits TPA-induced EBV-EA activation in Raji cells, reducing the relative activation ratio to 6.9% of the positive control at 1000 mol ratio/TPA while maintaining 70% Raji cell viability^[6].

Others

Faradiol (5 days after infiltration) reaches a maximum yield of 2.34 μg/mg dry weight in N. benthamiana leaves through transient co-expression of CoTXSS with CoCYP716A392 or CoCYP716A393^[1].
Faradiol (0.25-0.61 μg/mg dry weight) accumulates at low levels in Calendula officinalis flowers^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Cell Cytotoxicity Assay^[4]

Cell Line:

human leukemic cell lines NB4 and K562
Concentration:

25 mM (stock); 100 μM (assay starting concentration; seven two-fold serial dilutions)
Incubation Time:

24 h and 48 h
Result:

IC₅₀ values were 32.47 μM (NB4, 24 h), 30.60 μM (NB4, 48 h), 132.80 μM (K562, 24 h), and 60.15 μM (K562, 48 h).

Cell Cytotoxicity Assay^[7]

Cell Line:

NCI 60 human cancer cell lines (lung, colon, melanoma, renal, ovarian, brain, and leukemia)
Concentration:

10^-4 M starting; five concentrations at ten-fold dilutions
Incubation Time:

48 h
Result:

Exhibited marked cytotoxicity against leukemia cell lines CCRF-CEM (GI₅₀, 3.2 µM), K-582 (GI₅₀, 4.2 µM), and SR (GI₅₀, 3.5 µM), and against non-small cell lung cancer EKVX (GI₅₀, 2.2 µM).
Showed moderate activity against the other cells (GI₅₀, 10.5-86.9 µM).

In Vivo

Anti-cancerOthers

Anti-cancer

Faradiol (0.2 μmol/mouse; topical administration; before each TPA administration (twice weekly); 20 weeks) inhibits TPA-promoted skin tumor formation in DMBA (HY-W011845)-initiated female ICR mice, with 40% of mice bearing tumors at week 20 and an average of 2.9 tumors per mouse^[9].

Others

Faradiol (120 µg/cm²; topical administration; single administration; 6 h) produces 73% inhibition of croton oil-induced mouse ear edema^[5].
Faradiol (compound 9) (1 mg/ear; topical administration; single dose; 30 min before TPA) inhibits TPA-induced ear edema in ICR mice, with an ID₅₀ of 0.2 mg/ear^[8].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:

Albino Swiss (male, 28-30 g, Charles Rivers, Calco, Italy)^[5]
Dosage:

120 µg/cm² (0.27 µmole/cm²)
Administration:

topical; single application; 6 h
Result:

Reduced ear oedema to 2.0 mg, corresponding to 73% inhibition.
Control oedema was 7.4 mg.

Animal Model:

ICR (five mice per group)^[9]
Dosage:

1 mg/ear
Administration:

topical; single application; 30 min before TPA
Result:

Inhibited TPA-induced ear edema with an ID₅₀ of 0.2 mg/ear and an inhibitory ratio of 94% at 1 mg/ear.

Animal Model:

ICR (female, 7 weeks old)^[10]
Dosage:

0.2 μmol/mouse
Administration:

topical; once 30 min before each TPA application (twice weekly); 20 weeks
Result:

In the DMBA plus TPA plus faradiol group, the first tumor appeared at week 10.
At week 20, 40% of mice were tumor-bearing.
The faradiol group had an average of 2.9 tumors per mouse at week 20.
Faradiol caused a 66% reduction in the average number of tumors per mouse at week 20.

Related Protocols :

Chemical Information

CAS. Nr. 20554-95-4
Molecular Weight 442.72
Formel C₃₀H₅₀O₂
SMILES

CC1(C)[C@@H](O)CC[C@]2(C)[C@@]3([H])CC[C@]4([H])[C@@]5([H])[C@H](C)C(C)=CC[C@@](C)5[C@@H](O)C[C@](C)4[C@@](C)3CC[C@@]12[H]
Structure Classification
- Terpenoids
- Triterpenes
Initial Source
Versand

Room temperature in continental US; may vary elsewhere.
Speicherung

Please store the product under the recommended conditions in the Certificate of Analysis.

Reinheit & Dokumentation

Select Batch:

Reinheit: 99.98%

Assay: 99.98%

ee.: 99.98%

Data Sheet (284 KB)
COA (2659 KB)
Elemental Analysis Report (2659 KB)
HNMR (2659 KB)
CNMR (2659 KB)
RP-HPLC (2659 KB)
NP-HPLC (2659 KB)
MS (2659 KB)
LCMS (2659 KB)
IR (2659 KB)
GC (2659 KB)
OR (2659 KB)
SDS-PAGE (2659 KB)
SEC-HPLC (2659 KB)
Other Report (2659 KB)
Handling Instructions (2659 KB)

Verweise

[1]. Golubova D, et al. Biosynthesis and bioactivity of anti-inflammatory triterpenoids in Calendula officinalis. Nature communications. 2025 Jul 28;16(1):6941.

[2]. Fronza M, et al. Determination of the wound healing effect of Calendula extracts using the scratch assay with 3T3 fibroblasts. Journal of ethnopharmacology. 2009 Dec 10;126(3):463-7.

[3]. Vela Gurovic MS, et al. Cytotoxic effects induced by combination of heliantriol B2 and dequalinium against human leukemic cell lines. Phytotherapy Research. 2011 Apr;25(4):603-10.

[4]. Zitterl-Eglseer K, et al. Anti-oedematous activities of the main triterpendiol esters of marigold (Calendula officinalis L.). Journal of ethnopharmacology. 1997 Jul;57(2):139-44.

[5]. Ukiya M, et al. Constituents of Compositae plants III. Anti-tumor promoting effects and cytotoxic activity against human cancer cell lines of triterpene diols and triols from edible chrysanthemum flowers. Cancer letters. 2002 Mar 08;177(1):7-12.

[6]. Dzubak P, et al. Pharmacological activities of natural triterpenoids and their therapeutic implications. Natural product reports. 2006 Jun 1;23(3):394-411.

[7]. Ukiya M, et al. Constituents of compositae plants. 2. Triterpene diols, triols, and their 3-o-fatty acid esters from edible chrysanthemum flower extract and their anti-inflammatory effects. Journal of agricultural and food chemistry. 2001 Jul;49(7):3187-97.

[8]. Yasukawa K, et al. Inhibitory effect of heliantriol C; a component of edible Chrysanthemum, on tumor promotion by 12-O-tetradecanoylphorbol-13-acetate in two-stage carcinogenesis in mouse skin. Phytomedicine : international journal of phytotherapy and phytopharmacology. 1998 May;5(3):215-8. [Content Brief]

Calculators

Molaritätsrechner

Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

Mass Mass

Konzentration Konzentration

Volumen Volumen

Molecular Weight Molecular Weight

Verdünnungsrechner

Konzentration _{(Stammlösung)} × Volumen _{(Stammlösung)} = Konzentration _{(Ziellösung)} × Volumen _{(Ziellösung)}

Konzentration _{(Stammlösung)} Konzentration _{(Stammlösung)}

Volumen _{(Stammlösung)} Volumen _{(Stammlösung)}

Konzentration _{(Ziellösung)} Konzentration _{(Ziellösung)}

Volumen _{(Ziellösung)} Volumen _{(Ziellösung)}

Help & FAQs

How should lyophilized recombinant proteins be reconstituted and stored?

1. Before opening the cap, centrifuge the vial at 13000 rpm for 20-30 seconds. This step will ensure that any lyophilized powder that may have adhered to the cap or walls is collected at the bottom of the vial, minimizing the risk of product loss.

Produktname:
Art. -Nr.:
Menge:
MCE Japan Authorized Agent:

Produktname:
CAS. Nr.:
Species:
Reinheit:
Menge:

Faradiol

Alle STAT Isoform-spezifische Produkte anzeigen

Alle Interleukin Related Isoform-spezifische Produkte anzeigen